A clinical study of VED-001 for the treatment of head and neck cancers
Latest Information Update: 04 Apr 2019
Price :
$35 *
At a glance
- Drugs VED 001 (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 04 Apr 2019 New trial record
- 27 Mar 2019 According to an Elicio Therapeutics media release, the company is planning to initiate this stuyd in the first half of 2020.